beta-Lactam-resistant Pseudomonas aeruginosa with modified penicillin-binding proteins emerging during cystic fibrosis treatment.
about
Crystal Structures of Penicillin-Binding Protein 3 from Pseudomonas aeruginosa: Comparison of Native and Antibiotic-Bound FormsPenicillin-binding proteins and bacterial resistance to beta-lactamsPenicillin-binding protein inactivation by human neutrophil myeloperoxidase.Coexistence and within-host evolution of diversified lineages of hypermutable Pseudomonas aeruginosa in long-term cystic fibrosis infections.Contribution of beta-lactamase hydrolysis and outer membrane permeability to ceftriaxone resistance in Enterobacter cloacae.Alterations in kinetic properties of penicillin-binding proteins of penicillin-resistant Streptococcus pneumoniae.Mechanism of resistance of an ampicillin-resistant, beta-lactamase-negative clinical isolate of Haemophilus influenzae type b to beta-lactam antibiotics.Cephalosporins in clinical development.Absence of penicillin-binding protein 4 from an apparently normal strain of Bacillus subtilisMultidrug-resistant organisms in cystic fibrosis: management and infection-control issues.Emerging cephalosporins.Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.The biochemical basis of antimicrobial and bacterial resistance.Modification of penicillin-binding proteins as mechanisms of beta-lactam resistance.Cloning and characterization of the Pseudomonas aeruginosa pbpB gene encoding penicillin-binding protein 3.Susceptibility to beta-lactam antibiotics of Pseudomonas aeruginosa overproducing penicillin-binding protein 3Cloning and expression of genes responsible for altered penicillin-binding proteins 3a and 3b in Haemophilus influenzae.Mechanism of action of cephalosporins and resistance caused by decreased affinity for penicillin-binding proteins in Bacteroides fragilis.Resistance of Pseudomonas aeruginosa to new beta-lactamase-resistant beta-lactams.Mutation of Pseudomonas aeruginosa specifying reduced affinity for penicillin G.Analysis of the sodium dodecyl sulfate-stable peptidoglycan autolysins of select gram-negative pathogens by using renaturing polyacrylamide gel electrophoresis.Identification of a streptococcal penicillin-binding protein that reacts very slowly with penicillin.Pseudomonas pseudomallei resistance to beta-lactam antibiotics due to alterations in the chromosomally encoded beta-lactamase.Plasmid-determined resistance to antimicrobial drugs and toxic metal ions in bacteria.The third generation cephalosporins.Correlation between lipopolysaccharide structure and permeability resistance in beta-lactam-resistant Pseudomonas aeruginosa.In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.When drug inactivation renders the target irrelevant to antibiotic resistance: a case story with beta-lactams.Resistance of Pseudomonas aeruginosa mutants with altered control of chromosomal beta-lactamase to piperacillin, ceftazidime, and cefsulodin.Analysis of penicillin-binding proteins (PBPs) in carbapenem resistant Acinetobacter baumanniiCarbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.Contribution of the MexAB-OprM multidrug efflux system to the beta-lactam resistance of penicillin-binding protein and beta-lactamase-derepressed mutants of Pseudomonas aeruginosa.In-vitro susceptibility of clinical isolates of Pseudomonas aeruginosa to beta-lactam and aminoglycoside antibiotics.
P2860
Q27665349-0B9CD0DA-2983-42BC-A34E-CC7E78687458Q28257231-AF4BE0E7-93EB-499A-892C-723F7AE75698Q34196670-DED194CE-9576-4DEA-AC3D-64B4CEC5E64AQ35350270-383B7BD1-6EC9-4075-88DC-B96DEE1B10F6Q35542647-44A16EB9-E513-467B-BAC8-5EE77E3D2D19Q35574144-85059D6E-E530-4265-BD0A-68739F0554DEQ35760731-6804BB71-A86C-46B1-BA7E-336390F1CABBQ35842532-F01BADED-8F78-405C-B690-BF33C3941D63Q36272474-598DCDBE-ED8F-417E-A89E-A2407F4249B3Q36670892-83418CA6-107F-44C6-92A7-E646EEFE44ADQ36989896-664B4FFB-9631-45B8-9604-37BB392DFE8EQ37190771-F787B167-DCBD-4F77-94C5-71A2746BDD7CQ37656243-68C15428-7015-4315-BFE9-60E5475AED16Q38958329-141593A8-EE34-464A-821D-4BA82778EDA9Q39742895-678093E3-560E-4791-B367-FB20E53E5361Q39780285-060D3CF8-951A-414D-B851-5804515FD8AEQ39784205-9C26931A-53BB-490A-9F2B-C95AA06448A0Q39827687-767B474B-3031-483C-AE5A-3A0CFB71BF77Q39832924-2F3D42A3-AEDC-4332-BB97-120AE4072B2BQ39849040-1F3094A2-DE5C-42D4-8E67-53BE3090986DQ39856451-5D36A080-B90D-46ED-8C44-75A3F332F687Q39897729-86BB1989-391C-478B-91D0-07FF1504A022Q39976852-1A8A42A5-F0C2-4A58-AFFC-F1E5A6533238Q40087113-F4445B69-A143-4133-921A-2DCC82973D36Q40161230-06D434B1-A4D7-4C14-80A7-B6A215741227Q40253708-B8650A0C-8271-4DE1-BA53-3637E2D16ED4Q40283275-03732190-5D7C-4FB2-893D-C5E315E9BA9BQ40751280-A31CD6F8-B093-4E8A-A190-076F710343A0Q40824709-68D9298F-EBF1-4A18-B3B1-ACD320AE936DQ42115498-10482AB7-7001-4686-BB11-AC2FC941EA6CQ42740162-9A39C431-7D39-41F6-9D1A-37BAB8828ECCQ46412289-02C9CC4A-77AD-4DD0-A0D9-34F37F114757Q54070064-8CA2D04C-D90E-4A5B-AC25-49374B738A2EQ54340360-FA3B274B-16B1-4F26-8359-8960E8501039
P2860
beta-Lactam-resistant Pseudomonas aeruginosa with modified penicillin-binding proteins emerging during cystic fibrosis treatment.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
1981年论文
@zh
1981年论文
@zh-cn
name
beta-Lactam-resistant Pseudomo ...... ing cystic fibrosis treatment.
@ast
beta-Lactam-resistant Pseudomo ...... ing cystic fibrosis treatment.
@en
type
label
beta-Lactam-resistant Pseudomo ...... ing cystic fibrosis treatment.
@ast
beta-Lactam-resistant Pseudomo ...... ing cystic fibrosis treatment.
@en
prefLabel
beta-Lactam-resistant Pseudomo ...... ing cystic fibrosis treatment.
@ast
beta-Lactam-resistant Pseudomo ...... ing cystic fibrosis treatment.
@en
P2093
P2860
P356
P1476
beta-Lactam-resistant Pseudomo ...... ing cystic fibrosis treatment.
@en
P2093
P2860
P304
P356
10.1128/AAC.19.5.705
P407
P577
1981-05-01T00:00:00Z